tradingkey.logo

PharmaCyte Biotech Inc

PMCB
查看详细走势图
0.741USD
+0.041+5.89%
收盘 02/06, 16:00美东报价延迟15分钟
5.04M总市值
亏损市盈率 TTM

PharmaCyte Biotech Inc

0.741
+0.041+5.89%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+5.89%

5天

-9.50%

1月

-10.70%

6月

-12.80%

今年开始到现在

+2.38%

1年

-50.26%

查看详细走势图

TradingKey PharmaCyte Biotech Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

PharmaCyte Biotech Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名213/392位。机构持股占比非常高,中期看,股价处于下降通道。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

PharmaCyte Biotech Inc评分

相关信息

行业排名
213 / 392
全市场排名
428 / 4521
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

PharmaCyte Biotech Inc亮点

亮点风险
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
业绩转盈
公司业绩转盈,最新年度盈利美元
估值合理
公司最新PE估值-0.66,处于3年历史合理位
机构减仓
最新机构持股434.85K股,环比减少46.71%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值80.00K
活跃度增加
近期活跃度增加,过去20天平均换手率4.02

分析师目标

根据 0 位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

PharmaCyte Biotech Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

PharmaCyte Biotech Inc简介

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
公司代码PMCB
公司PharmaCyte Biotech Inc
CEOSilverman (Joshua N)
网址https://pharmacyte.com/
KeyAI